Extracellular Vesicle Vaccine Platform for Broad Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine platforms are insufficient for a wide range of diseases, including viral, microbial, and cancerous infections, and there is a need for more effective and safe vaccines using extracellular vesicles as immunostimulants and antigen carriers.
Innovation Solution
Development of extracellular vesicles containing antigen proteins or genes encoding these proteins, derived from viruses, microorganisms, or cancer cells, to induce antigen-specific antibody and T cell responses, applicable in vaccine compositions and health functional foods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If extracellular vesicles are used as vaccine platforms, then immune response induction is improved, but application scope to various diseases is limited
Solution Approach 1:
The patent applies universality by developing a standardized extracellular vesicle platform that can deliver different antigen types (proteins, mRNA, DNA) for various diseases including viral infections, bacterial infections, and cancer. The platform maintains consistent immunostimulatory properties while adapting to different therapeutic targets through antigen selection, enabling broad application across multiple disease categories.
Solution Approach 2:
The patent utilizes parameter changes by modifying the cargo content of extracellular vesicles (proteins, mRNA, or DNA) while maintaining the core vesicle structure and immunostimulatory properties. This allows the same platform to be adapted for different diseases by changing the antigen type and sequence, thereby expanding application scope without compromising immune response induction.
2Adaptability or versatility
If existing vaccine platforms are used, then development is restricted to some diseases, but new platform development for various diseases is insufficient
Solution Approach 1:
The patent creates a universal vaccine platform using extracellular vesicles that can be applied to multiple disease types including viral infections, bacterial infections, and cancer. The standardized vesicle platform with consistent immunostimulatory properties allows rapid adaptation to different diseases by simply changing the antigen cargo, significantly improving vaccine development efficiency across diverse disease categories.
3Reliability
If extracellular vesicles are used as antigen carriers, then antigen-specific immune response is enhanced, but vaccine platform applicability to various infections remains limited
Solution Approach 1:
The patent applies parameter changes by modifying the antigen cargo (proteins, mRNA, or DNA) within the extracellular vesicle platform while maintaining the core vesicle structure and immunostimulatory properties. This enables the same platform to target different pathogens and diseases by changing the antigen sequence and type, thereby enhancing both antigen-specific immune response and platform applicability to various infections.
Data Source
AI summary
The present disclosure relates to an extracellular vesicle including an antigen protein or a gene encoding the antigen protein and use thereof, and more particularly, to: an extracellular vesicle including an antigen protein derived from a virus, a microorganism, or cancer cells, or a gene encoding the antigen protein; or a vaccine composition for the prevention or treatment of a viral infection, a microbial infection, or cancer, the vaccine composition including the extracellular vesicle. The extracellular vesicle or the vaccine composition including the extracellular vesicle, according to the present disclosure, is a platform that has stability and an excellent effect of inducing an antigen-specific immune response and can be applied to various diseases, and thus is expected to be effectively used in the field of development of a vaccine for the prevention or treatment of various diseases, including microbial infections or cancer.